Uğur Sener

1.1k total citations
68 papers, 665 citations indexed

About

Uğur Sener is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Uğur Sener has authored 68 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 25 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Uğur Sener's work include Glioma Diagnosis and Treatment (39 papers), Brain Metastases and Treatment (22 papers) and Meningioma and schwannoma management (6 papers). Uğur Sener is often cited by papers focused on Glioma Diagnosis and Treatment (39 papers), Brain Metastases and Treatment (22 papers) and Meningioma and schwannoma management (6 papers). Uğur Sener collaborates with scholars based in United States, Türkiye and Canada. Uğur Sener's co-authors include Adrienne Boire, Jian Campian, Mason Webb, Ján Remšík, Michael W. Ruff, Tejus Bale, Yudan Chi, Fadi Saadeh, Camille Derderian and Yaşar Zorlu and has published in prestigious journals such as Nature, Science and Journal of Clinical Oncology.

In The Last Decade

Uğur Sener

55 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uğur Sener United States 13 214 212 170 153 91 68 665
Jonathan B. Lamano United States 14 258 1.2× 125 0.6× 135 0.8× 223 1.5× 234 2.6× 23 653
Henry Ruiz-García United States 14 249 1.2× 162 0.8× 89 0.5× 112 0.7× 41 0.5× 38 552
Susan Chang United States 8 325 1.5× 102 0.5× 156 0.9× 66 0.4× 73 0.8× 24 547
Mohamed S Abdelbaki United States 12 191 0.9× 83 0.4× 137 0.8× 128 0.8× 120 1.3× 64 528
Antonella Cacchione Italy 15 345 1.6× 104 0.5× 174 1.0× 77 0.5× 39 0.4× 64 685
Matthew J. Shepard United States 14 88 0.4× 192 0.9× 114 0.7× 175 1.1× 21 0.2× 48 515
David Altshuler United States 11 249 1.2× 97 0.5× 193 1.1× 107 0.7× 133 1.5× 22 570
Angela Di Giannatale Italy 19 113 0.5× 157 0.7× 420 2.5× 115 0.8× 98 1.1× 53 809
Amol Mehta United States 15 173 0.8× 126 0.6× 102 0.6× 88 0.6× 42 0.5× 40 697
Lucinda Aguirre‐Cruz Mexico 14 342 1.6× 84 0.4× 330 1.9× 72 0.5× 42 0.5× 38 794

Countries citing papers authored by Uğur Sener

Since Specialization
Citations

This map shows the geographic impact of Uğur Sener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uğur Sener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uğur Sener more than expected).

Fields of papers citing papers by Uğur Sener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uğur Sener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uğur Sener. The network helps show where Uğur Sener may publish in the future.

Co-authorship network of co-authors of Uğur Sener

This figure shows the co-authorship network connecting the top 25 collaborators of Uğur Sener. A scholar is included among the top collaborators of Uğur Sener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uğur Sener. Uğur Sener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remšík, Ján, Xinran Tong, Russell Kunes, et al.. (2025). Interferon-γ orchestrates leptomeningeal anti-tumour response. Nature. 643(8073). 1087–1096. 8 indexed citations
2.
Sener, Uğur, Jessica Wilcox, & Adrienne Boire. (2025). Leptomeningeal Disease: Current Approaches and Future Directions. Current Neurology and Neuroscience Reports. 25(1). 25–25.
3.
Neth, Bryan J., Mason Webb, Jonathan Schwartz, et al.. (2025). Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis. Journal of Neuro-Oncology. 173(3). 635–643.
4.
Sener, Uğur, Joon H. Uhm, Tufia C. Haddad, & Joshua C. Pritchett. (2024). Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic. Current Oncology Reports. 26(11). 1271–1276. 2 indexed citations
5.
Webb, Mason, et al.. (2024). Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas. Current Oncology Reports. 26(4). 377–390. 8 indexed citations
6.
Breen, William G., Mark R. Waddle, J. Qian, et al.. (2024). Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis. Neuro-Oncology Advances. 6(1). vdae034–vdae034. 6 indexed citations
7.
Sener, Uğur, et al.. (2024). Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design. Neuro-Oncology Advances. 6(1). vdae039–vdae039. 4 indexed citations
8.
Lehrer, Eric J., et al.. (2024). Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma. International Journal of Molecular Sciences. 25(19). 10570–10570. 7 indexed citations
9.
Sener, Uğur, Fredric B. Meyer, Anita Mahajan, et al.. (2024). EXTH-81. A RARE CASE OF RELENTLESSLY PROGRESSIVE METASTATIC PINEOCYTOMA MANAGED WITH SEQUENTIAL MULTIMODAL THERAPY. Neuro-Oncology. 26(Supplement_8). viii255–viii255.
10.
Jusué-Torres, Ignacio, et al.. (2024). Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan. World Neurosurgery. 190. 291–296. 1 indexed citations
11.
Webb, Mason, et al.. (2024). A case series of osseous metastases in patients with glioblastoma. Medicine. 103(27). e38794–e38794.
12.
Sener, Uğur, et al.. (2024). Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer. Clinical Colorectal Cancer. 24(1). 98–100. 1 indexed citations
13.
Maritan, Sarah M., Zhimin Zeng, Zhengfei Zhu, et al.. (2024). Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis. Heliyon. 10(9). e29668–e29668. 5 indexed citations
14.
Uhm, Joon H., Michael W. Ruff, Mason Webb, et al.. (2024). CTNI-82. BELZUTIFAN TREATMENT OF VHL-ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMA. Neuro-Oncology. 26(Supplement_8). viii116–viii116.
15.
Webb, Mason, et al.. (2023). Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions. SHILAP Revista de lepidopterología. 7(2). 97–110. 14 indexed citations
16.
Webb, Mason, Bryan J. Neth, Jamie J. Van Gompel, et al.. (2023). Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neuro-Oncology Advances. 5(1). vdad123–vdad123. 4 indexed citations
17.
Schaff, Lauren, Dean Carlow, Ryan Schofield, et al.. (2022). Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC Cancer. 22(1). 60–60. 8 indexed citations
18.
Remšík, Ján, Xinran Tong, Uğur Sener, et al.. (2021). Abstract 1751: Decoding the immune system response to leptomeningeal metastasis. Cancer Research. 81(13_Supplement). 1751–1751. 1 indexed citations
19.
Sener, Uğur, Ramazan Uygur, Özgür Kurt, et al.. (2015). Protective Effects of Curcumin against Formaldehyde-induced Renal Toxicity in Rats. West Indian Medical Journal. 4 indexed citations
20.
Ceylan, Savaş, et al.. (1992). Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine. Research in Experimental Medicine. 192(1). 23–33. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan B. Lamano Breakdown of academic impact, for papers by Henry Ruiz-García Breakdown of academic impact, for papers by Susan Chang Breakdown of academic impact, for papers by Mohamed S Abdelbaki Breakdown of academic impact, for papers by Antonella Cacchione Breakdown of academic impact, for papers by Matthew J. Shepard Breakdown of academic impact, for papers by David Altshuler Breakdown of academic impact, for papers by Angela Di Giannatale Breakdown of academic impact, for papers by Amol Mehta Breakdown of academic impact, for papers by Lucinda Aguirre‐Cruz
Rankless by CCL
2026